arsenic trioxide has been researched along with Hemorrhage in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, S; Shi, J; Wang, C; Wang, Y; Yang, H; Zuo, N | 1 |
| Ahluwalia, J; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, N; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U | 1 |
| Stahl, M; Tallman, MS | 1 |
| Cao, F; Hou, W; Jin, B; Li, H; Sun, J; Yan, L; Zhang, Y; Zhao, H; Zhou, J | 1 |
| Fan, D; Fu, J; Ge, F; Hou, J; Hou, W; Li, H; Li, X; Sun, J; Wang, P; Wang, S; Yang, K; Yang, Y; Zhang, Y; Zhao, H; Zhou, J | 1 |
| Chen, L; Chen, SJ; Chen, Z; Cui, W; Gao, MQ; Hu, J; Li, JM; Mi, JQ; Nie, RM; Shen, ZX; Wang, J; Wang, KK; Wang, ZY; Xi, XD; Zhao, LL; Zhu, HM | 1 |
| Huang, J; Shen, K; Yang, CL | 1 |
| Manji, GA; Tallman, MS | 1 |
| Choudhry, A; DeLoughery, TG | 1 |
| Guo, P; Hu, Y; Qiao, Z; Shen, G; Song, S; Wang, J; Yang, L; Zhang, X; Zhou, H | 1 |
| Hu, Y; Qiao, Z; Song, S; Yang, L; Zhang, X; Zhou, H | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M | 1 |
| Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Wu, F; Zhao, W | 1 |
3 review(s) available for arsenic trioxide and Hemorrhage
| Article | Year |
|---|---|
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Mortality; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Time Factors; Tretinoin | 2019 |
Bleeding and thrombosis in acute promyelocytic leukemia.
Topics: Antifibrinolytic Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Clinical Trials as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Disseminated Intravascular Coagulation; Factor VIIa; Factor VIII; Fibrinogen; Fibrinolysis; Hemorrhage; Heparin; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Plasma; Platelet Count; Platelet Transfusion; Recombinant Proteins; Thromboplastin; Thrombosis; Treatment Failure; Tretinoin | 2012 |
Treatment concepts of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2005 |
2 trial(s) available for arsenic trioxide and Hemorrhage
| Article | Year |
|---|---|
Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Blood Coagulation; Cell-Derived Microparticles; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prospective Studies; Thromboplastin | 2021 |
Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Creatinine; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2017 |
9 other study(ies) available for arsenic trioxide and Hemorrhage
| Article | Year |
|---|---|
Extracellular Traps Increase Burden of Bleeding by Damaging Endothelial Cell in Acute Promyelocytic Leukaemia.
Topics: Arsenic Trioxide; Endothelial Cells; Extracellular Traps; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2022 |
Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Thrombosis; Tretinoin | 2023 |
Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Remission Induction; Treatment Outcome; Young Adult | 2018 |
Diffuse Pulmonary Alveolar Hemorrhage Secondary to All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia.
Topics: Adult; Arsenic Trioxide; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Tretinoin | 2018 |
Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Survival Rate; Time Factors; Treatment Failure; Tretinoin | 2011 |
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
Topics: Adolescent; Adult; Annexin A2; Antineoplastic Agents; AraC Transcription Factor; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Female; Fibrinolysin; Gene Expression Regulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen Activators; Repressor Proteins; RNA, Messenger; Tissue Plasminogen Activator; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |
[The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Down-Regulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin | 2001 |
Use of Novoseven for arsenic trioxide-induced bleeding in PML.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Factor VII; Factor VIIa; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Lung Diseases; Oxides; Recombinant Proteins | 2006 |
Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Hemorrhage; Hemostasis; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 2001 |